Compare PDI & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDI | DVA |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 8.2B |
| IPO Year | N/A | 1995 |
| Metric | PDI | DVA |
|---|---|---|
| Price | $18.21 | $111.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $145.00 |
| AVG Volume (30 Days) | ★ 1.5M | 750.1K |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 13.81% | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | N/A | ★ $13,317,965,000.00 |
| Revenue This Year | N/A | $6.50 |
| Revenue Next Year | N/A | $2.97 |
| P/E Ratio | ★ N/A | $11.41 |
| Revenue Growth | N/A | ★ 5.14 |
| 52 Week Low | $15.45 | $108.67 |
| 52 Week High | $19.60 | $179.60 |
| Indicator | PDI | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.53 | 35.62 |
| Support Level | $18.03 | $110.33 |
| Resistance Level | $18.24 | $115.82 |
| Average True Range (ATR) | 0.12 | 2.42 |
| MACD | 0.07 | -0.18 |
| Stochastic Oscillator | 93.05 | 28.77 |
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.